KALA BIO Inc

KALA

0.751USD

-0.010-1.34%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

KALA BIO Inc's Score

Industry at a Glance

Industry Ranking

204 / 407

Overall Ranking

357 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Hold

Current Rating

1.500

Target Price

+80.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

KALA BIO Inc Highlights

StrengthsRisks

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Overvalued

The company’s latest PE is -0.13, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.49M shares, decreasing 21.83% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 170.38K shares of this stock.

The company's current financial score is 6.82, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.82

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.74

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.77

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.04

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 5.76, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.13, which is -15330.96% below the recent high of 19.24 and -2511.40% above the recent low of -3.30.

Score

Industry at a Glance

Previous score

5.76

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 204/407

No Data

The company’s current earnings forecast score is 6.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for KALA BIO Inc is 1.50, with a high of 1.50 and a low of 1.50.

Score

Industry at a Glance

Previous score

6.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 4.15, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 1.39 and the support level at 0.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.46

Change

-0.31

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cormorant Asset Management, LP

603.03K

--

Perceptive Advisors LLC

543.75K

+884.56%

Point72 Asset Management, L.P.

Star Investors

469.23K

--

SR One Capital Management, LP

598.94K

--

Baker Bros. Advisors LP

310.56K

-74.16%

Woodline Partners LP

300.15K

+15.99%

The Vanguard Group, Inc.

Star Investors

170.38K

+11.52%

Adar1 Capital Management LLC

149.83K

-49.88%

UBS O'Connor LLC

138.56K

-18.93%

Worth Venture Partners, LLC

83.96K

+72.71%



1

2



The company’s current risk assessment score is 1.04, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -2.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

KALA BIO Inc

KALA

5.20 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Amicus Therapeutics Inc

FOLD

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.36 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment